These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

619 related articles for article (PubMed ID: 23918605)

  • 1. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.
    Hartmann C; Hentschel B; Simon M; Westphal M; Schackert G; Tonn JC; Loeffler M; Reifenberger G; Pietsch T; von Deimling A; Weller M;
    Clin Cancer Res; 2013 Sep; 19(18):5146-57. PubMed ID: 23918605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
    Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP
    Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
    Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J
    World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors.
    Mellai M; Piazzi A; Caldera V; Monzeglio O; Cassoni P; Valente G; Schiffer D
    J Neurooncol; 2011 Nov; 105(2):345-57. PubMed ID: 21643842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.
    Yang P; Zhang W; Wang Y; Peng X; Chen B; Qiu X; Li G; Li S; Wu C; Yao K; Li W; Yan W; Li J; You Y; Chen CC; Jiang T
    Oncotarget; 2015 Dec; 6(38):40896-906. PubMed ID: 26503470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients.
    Amelot A; De Cremoux P; Quillien V; Polivka M; Adle-Biassette H; Lehmann-Che J; Françoise L; Carpentier AF; George B; Mandonnet E; Froelich S
    PLoS One; 2015; 10(7):e0130596. PubMed ID: 26158269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas.
    Juratli TA; Kirsch M; Geiger K; Klink B; Leipnitz E; Pinzer T; Soucek S; Schrock E; Schackert G; Krex D
    J Neurooncol; 2012 Dec; 110(3):325-33. PubMed ID: 23015095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival.
    Leu S; von Felten S; Frank S; Vassella E; Vajtai I; Taylor E; Schulz M; Hutter G; Hench J; Schucht P; Boulay JL; Mariani L
    Neuro Oncol; 2013 Apr; 15(4):469-79. PubMed ID: 23408861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Impact of IDH1 Mutation and MGMT Promoter Methylation on Recurrence-Free Interval in Glioblastoma Patients Treated With Radiotherapy and Chemotherapeutic Agents.
    Kurdi M; Shafique Butt N; Baeesa S; Alghamdi B; Maghrabi Y; Bardeesi A; Saeedi R; Al-Sinani T; Alghanmi N; Bari MO; Samkari A; Lary AI
    Pathol Oncol Res; 2021; 27():1609778. PubMed ID: 34257620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling.
    Reifenberger G; Weber RG; Riehmer V; Kaulich K; Willscher E; Wirth H; Gietzelt J; Hentschel B; Westphal M; Simon M; Schackert G; Schramm J; Matschke J; Sabel MC; Gramatzki D; Felsberg J; Hartmann C; Steinbach JP; Schlegel U; Wick W; Radlwimmer B; Pietsch T; Tonn JC; von Deimling A; Binder H; Weller M; Loeffler M;
    Int J Cancer; 2014 Oct; 135(8):1822-31. PubMed ID: 24615357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
    Weller M; Felsberg J; Hartmann C; Berger H; Steinbach JP; Schramm J; Westphal M; Schackert G; Simon M; Tonn JC; Heese O; Krex D; Nikkhah G; Pietsch T; Wiestler O; Reifenberger G; von Deimling A; Loeffler M
    J Clin Oncol; 2009 Dec; 27(34):5743-50. PubMed ID: 19805672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma.
    Laxton RC; Popov S; Doey L; Jury A; Bhangoo R; Gullan R; Chandler C; Brazil L; Sadler G; Beaney R; Sibtain N; King A; Bodi I; Jones C; Ashkan K; Al-Sarraj S
    Neuro Oncol; 2013 Dec; 15(12):1635-43. PubMed ID: 24158110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
    Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
    Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IDH1 mutation of gliomas with long-term survival analysis.
    Myung JK; Cho HJ; Park CK; Kim SK; Phi JH; Park SH
    Oncol Rep; 2012 Nov; 28(5):1639-44. PubMed ID: 22922798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
    van den Bent MJ; Dubbink HJ; Marie Y; Brandes AA; Taphoorn MJ; Wesseling P; Frenay M; Tijssen CC; Lacombe D; Idbaih A; van Marion R; Kros JM; Dinjens WN; Gorlia T; Sanson M
    Clin Cancer Res; 2010 Mar; 16(5):1597-604. PubMed ID: 20160062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.
    Molenaar RJ; Verbaan D; Lamba S; Zanon C; Jeuken JW; Boots-Sprenger SH; Wesseling P; Hulsebos TJ; Troost D; van Tilborg AA; Leenstra S; Vandertop WP; Bardelli A; van Noorden CJ; Bleeker FE
    Neuro Oncol; 2014 Sep; 16(9):1263-73. PubMed ID: 24510240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.
    Arita H; Yamasaki K; Matsushita Y; Nakamura T; Shimokawa A; Takami H; Tanaka S; Mukasa A; Shirahata M; Shimizu S; Suzuki K; Saito K; Kobayashi K; Higuchi F; Uzuka T; Otani R; Tamura K; Sumita K; Ohno M; Miyakita Y; Kagawa N; Hashimoto N; Hatae R; Yoshimoto K; Shinojima N; Nakamura H; Kanemura Y; Okita Y; Kinoshita M; Ishibashi K; Shofuda T; Kodama Y; Mori K; Tomogane Y; Fukai J; Fujita K; Terakawa Y; Tsuyuguchi N; Moriuchi S; Nonaka M; Suzuki H; Shibuya M; Maehara T; Saito N; Nagane M; Kawahara N; Ueki K; Yoshimine T; Miyaoka E; Nishikawa R; Komori T; Narita Y; Ichimura K
    Acta Neuropathol Commun; 2016 Aug; 4(1):79. PubMed ID: 27503138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.